AICA Flux Enhancer™




The AICA Flux Enhancer™ has the possibility to be used in the manufacturing of different medications and used for treatment in conjunction with other methods.


AICAr has been used in trials and actual manufacturing of medication for:


  • Macular Degeneration
  • Ocular Inflammation
  • Heart Disease
  • Cancer
  • Acute Myeloid Leukemia
  • So much more







Special features

  • Makes Use of a Substance Easily Absorbed By Cells
  • Easily Applied to Bacterial Strains
  • Additional Strains Can Be Created
  • Can Be Used on a Larger Scale
  • Can Be Combined with Strains Created Through Genetic Engineering




The AICA Flux Enhancer™ is readily accepted by all types of cells from bacterial to mammalian. Some applications include metabolic engineering in microbes where increased biosynthetic activity results in enhanced lipid, isoprenoid, and carbohydrate synthesis. The analogue especially increases flux in PRPP pathways due to reduced RNA turnover leading to increased synthesis of histidine, tryptophan, and AICAR. Another application is in the detection of microbial species via mRNA accumulator. Using the analogue some mRNA species are increased to levels like rRNA making it an excellent approach to readily distinguish bacterial species and strains. Finally, there is increased protein secretion in yeast and possibly enhanced differentiation in mammalian cells. It is postulated that the increased energy charge from reduced RNA turnover promotes biosynthetic activity and cellular differentiation.

Materials needed to produce the AICA Flux Enhancer™:

  • Ethanol
  • Phosphorous Pentasulfide
  • Sodium Hydroxide
  • HPLC water
  • Glass bottle


The AICA Flux Enhancer™ is covered by United States Utility Patent: 11,254,958




For additional information, licensing opportunities, and a full prospectus on the AICA Flux Enhancer™  contact:




VP of Business Development